Introduction {#Sec1}
============

Lymphomas account for approximately 12% of total mediastinal tumors and represent heterogeneous histological subtypes^[@CR1]^. Lymphomas involving the mediastinum exhibit a wide age range, occurring in both pediatric and adult patients^[@CR2]^.

T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL) occurs most frequently in childhood but is also observed in adults^[@CR3]^. Classical Hodgkin lymphoma (CHL) peaks at 15--35 years of age and in late life, and it usually presents with cervical lymphadenopathy. CHL patients often have mediastinal masses^[@CR4]^. Primary mediastinal large B-cell lymphoma (PMBL), which arises from thymic medullary B-cells, typically occurs in young adults^[@CR5]^. Mucosa-associated lymphoid tissue (MALT) lymphoma, diffuse large B cell lymphoma (DLBCL), and mediastinal gray-zone lymphoma have also been reported in adults and elderly individuals^[@CR6],\ [@CR7]^.

The clinical and radiological presentations of lymphomas involving the mediastinum are complex and nonsepcific^[@CR8],\ [@CR9]^. The initial and differential diagnoses of different histological subtypes are confused by clinicians and radiologists in some cases. Moreover, some subtypes demonstrate similar morphological features, representing serious challenges for pathological diagnosis^[@CR7],\ [@CR10]^. The clinical and radiological findings are useful to determine the appropriate staging and management.

Previous studies have focused on a single histological subtype, such as T-LBL/T-ALL or PMBL. However, detailed descriptions of clinicopathological and clinicoradiological comparisons between these subtypes are rare. Moreover, few studies have analyzed the clinicopathological features of different subtypes of lymphomas involving the mediastinum in pediatric patients^[@CR11]--[@CR13]^. Studies clarifying the differences in histological distribution, clinical spectrum, and radiological features between pediatric and adult patients are limited.

In this study, we conducted a retrospective analysis of the clinical, radiological, morphological, and immunophenotypical features of lymphomas involving the mediastinum, and we further compared the differences between pediatric and adult patients.

Results {#Sec2}
=======

Morphological and immunohistochemical findings {#Sec3}
----------------------------------------------

T-LBL/T-ALL, CHL, PMBL, DLBCL, and MALT lymphomas were identified in 31, 12, 6, 2, and 1 cases, respectively. The immunohistochemical results are shown in Supplementary Tables [1](#MOESM1){ref-type="media"} and [2](#MOESM1){ref-type="media"}.

T-LBL/T-ALL were composed of small to medium-sized lymphoblasts with sparse cytoplasm and irregular nuclei. Tumor cells were commonly positive for TDT (21/26, 80.8%), CD3 (29/31, 93.5%), and CD7 (25/27, 92.6%), and they were variably positive for CD5 (16/24, 66.7%), CD99 (14/19, 73.7%), CD2 (12/18, 66.7%), and CD1a (13/21, 61.9%).

CHLs consisted of 11 cases of nodular sclerosis CHL (NSCHL) and 1 case of lymphocyte-rich CHL. NSCHL morphologically characterized in collagen bands surrounding nodules and Reed-Stenberg cells. CHL tumor cells were positive for PAX5 (10/12, 83.3%), CD30 (12/12, 100%), CD15 (9/12, 75.0%), CD20 (4/12, 33.3%) and CD79a (2/9, 22.2%).

PMBLs showed medium to large cells with round or lobulated nuclei and abundant cytoplasm. PMBLs expressed B-cell markers including PAX5 (5/5, 100%), CD20 (5/6, 83.3%) and CD79a (4/5, 80.0%). PMBL tumor cells were frequently positive for CD30 (3/5, 60.0%) and CD23 (4/5, 80.0%).

Systemic DLBCLs involving the mediastinum demonstrated the same pathological features to nodular DLBCLs. The MALT lymphoma was composed of small lymphocytes and monocytoid cells, which were positive for B-cell markers with low Ki-67 expression.

Clinical characteristics {#Sec4}
------------------------

The clinical characteristics of the 52 patients are summarized in Table [1](#Tab1){ref-type="table"}. The comparison between pediatric and adult patients is shown in Table [2](#Tab2){ref-type="table"}, and the comparisons among the main histological subtypes are shown in Table [3](#Tab3){ref-type="table"}.Table 1Clinical presentations of 52 cases with lymphomas involving the mediastinum.Case no.Age (y)/GenderHistological subtypeSymptomLN involvementLDH (U/L)StageResponse/Follow-up (m)CoughDyspneaChest painOthers**Pediatric patients**14/FT-LBL/T-ALLYNNNC896IIIPD/UT25MT-LBL/T-ALLYNYNN563IVCR/UT35/MT-LBL/T-ALLYYNFeverCNAIVDOD (6)45/FT-LBL/T-ALLYYNNN766IIICR/UT56/MT-LBL/T-ALLNYYNeck painC1102IVDOD (4)66/MT-LBL/T-ALLYNNFeverN398IVPR/UT76/FT-LBL/T-ALLNNNNeck enlargementC and A326IVCR/UT86/MT-LBL/T-ALLYYYNC and A1882IVDOD (5)97/MT-LBL/T-ALLYYNNMd635IIIPR/UT107/MT-LBL/T-ALLYNNFeverMdNAIVCR/NR (10)117/FT-LBL/T-ALLNNNNeck enlargementC344IVCR/NR (15)128/MT-LBL/T-ALLYYNNMd628IVCR/NR (30)139/FT-LBL/T-ALLYYNNC419IVCR/UT149/MT-LBL/T-ALLYNNNC2289IIICR/UT1511/MT-LBL/T-ALLYNNNC271IVDOD (7)1611/MT-LBL/T-ALLYNYNN795IVCR/UT1711/MT-LBL/T-ALLYNNFeverC, Ax and Ab285IVPR/UT1812/FT-LBL/T-ALLNYYSVCSC, Ax and Ab292IVDOD (8)1913/MT-LBL/T-ALLYYNFeverC, Ax, and Md759IVPD/UT2013/MT-LBL/T-ALLNYNDysphagiaNA297IIICR/UT2113/MT-LBL/T-ALLYNNFeverC and Ab2403IVCR/UT2214/MT-LBL/T-ALLNYNNCNAIVCR/NR (32)2318/MT-LBL/T-ALLYNNNC, Ax and Ab987IVCR/NR (12)2418/FT-LBL/T-ALLYNYFeverC, Ax and Md386IVDOD (7)254/MCHLNNNFeverAbdominal LV368IIICR/NR (14)265/MCHLYNNNC, Ax and Md378IICR/NR (24)275/FCHLNNNNC252IIIPR/NR (14)287/MCHLYNNFeverCNAIICR/NR (31)2910/FCHLYNNFeverC and MdNAIICR/NR (32)3013/MCHLNYYNC and Md394IIIPR/UT3114/MCHLNNNNeck enlargementC, Ax and Md200IICR/UT**Adult patients**3220/MT-LBL/T-ALLYNYFeverC227IVCR/NR (10)3320/MT-LBL/T-ALLNNNNC and Md264IVPD/UT3428/MT-LBL/T-ALLYNNNC, Ax, and Ab2286IVCR/UT3531/MT-LBL/T-ALLYNNFever, neck enlargementC, Ax, Md and Ab189IVPR/NR (32)3634/MT-LBL/T-ALLYNNNC972IIPD/UT3742/MT-LBL/T-ALLNNYNeck enlargementC, Md and I245IIICR/UT3854/FT-LBL/T-ALLNNYFeverC, Md and I233IIIPD/Relapsed3921/FCHLYNNFeverC, M432IIICR/NR (16)4022/FCHLNNNNCNAIICR/NR (35)4123/MCHLNNNNC and Md152IICR/NR (20)4225/FCHLNNNNC and M461IIIPR/NR (20)4334/FCHLNNNNCNAIICR/NR (14)4423/FPMBLNNYNC225IIICR/NR (33)4525/FPMBLYNNNeck enlargementC and Md156IIPD/UT4627/FPMBLNNYNNANAIICR/NR (31)4728/FPMBLNNYNNNAICR/NR (24)4836/MPMBLYNNNC and MdNAIICR/UT4944/FPMBLNNYNNNAICR/NR (30)5052/FMALTNNYFeverC and Md159IIPR/NR (23)5134/MDLBCLYNNFeverC356IVPR/NR (29)5264/MDLBCLYNNNMdNAIIPR/NR (20)Abbreviations: Ab, abdominal; Ax, axillary; C, cervical; CHL, classical Hodgkin lymphoma; CR, complete remission; D, diffuse large B-cell lymphoma; DOD, dead of disease; F, female; LN, lymph node; I,inguinal; MALT, mucosa associated lymphoid tissue lymphoma; Md, mediastinal node; M, male; N, no; NA, not available; NSCHL, nodular sclerosis classical Hodgkin lymphoma; NR, no relapse; PMBL, primary mediastinal large B-cell lymphoma; PD, progressing disease; PR, partial remission; T-LBL, T-cell lymphoblastic lymphoma/T-cell lymphoblastic leukemia; UT, under treatment; Y, yes; SVCS, superior vena cava syndrome. Table 2Comparisons of histological subtypes, clinical features, and radiological findings between pediatric and adult patients.T, n = 52, no. (%)P, n = 31, no. (%)A, n = 21, no. (%)*P*-value (P vs. A)Median age, years (range)13.0 (4--64)8.0 (4--18)28.0 (20--64)M:F32:2022:910:110.089**Histological subtype** T-LBL/T-ALL31/52 (59.6)24/31 (77.4)7/21 (33.3)**0.001** CHL12/52 (23.1)7/31 (22.6)5/21 (23.8)0.918 PMBL6/52 (11.5)0/31 (0)6/21 (28.6)**0.003** MALT1/52 (1.9)0/31 (0)1/21 (4.8)0.404 DLBCL2/52 (3.8)0/31 (0)2/21 (9.5)0.158**Clinical symptom** Cough30/52 (57.7)21/31 (67.7)9/21 (42.9)0.075 Dyspnea12/52 (23.1)12/31 (38.7)0/21 (0)**0.001** Chest pain15/52 (28.8)7/31 (22.6)8/21 (38.1)0.226 Fever16/52 (30.8)10/31 (32.2)6/21 (28.6)0.777**Clinical stage** Stage I2/52 (3.8)0/31 (0)2/21 (9.5)0.158 Stage II13/52 (25.0)4/31 (12.9)9/21 (42.9)**0.034** Stage III13/52 (25.0)8/31 (25.8)5/21 (23.8)0.870 Stage IV24/52 (46.2)19/31 (61.3)5/21 (23.8)**0.008**Mortality rate6/52 (11.5)6/31 (19.4)0/21 (0)**0.070**Tumor size (cm)9.37 ± 3.249.52 ± 3.229.07 ± 3.420.700Ratio of TD to MTD0.47 ± 0.170.52 ± 0.170.38 ± 0.14**0.015Tumor compression or encasement** Blood vessels encasement29/35 (82.9)21/23 (91.3)8/12 (66.7)0.151 Pericardiaum23/35 (65.7)16/23 (69.6)7/12 (58.3)0.709 Trachea19/35 (54.3)13/23 (56.5)6/12 (50.0)0.736**Complication** Pleural effussion23/35 (65.7)18/23 (78.3)5/12 (41.7)0.059 Pericardial effusion14/35 (40.0)11/23 (47.8)3/12 (25.0)0.282 Pneumonia17/35 (48.6)11/23 (47.8)6/12 (25.0)1.000Abbreviations: T, total; P, pediatric patients; A, adult patients; TD, tumor diameter; MTD, maximum transthoracic diameter. Table 3Comparisons of clinical features, and radiographic findings among different histological subtypes.Total, n = 52, no. (%)T-LBL/T-ALL, n = 31, no. (%)CHL, n = 12, No. (%)PMBL, n = 6, No. (%)DLBCL, n = 2, no. (%)MALT, n = 1, no. (%)*P*-value (T-LBL/T-ALL vs. CHL)*P*-value (T-LBL/T-ALL vs. PMBL)Median age, years (range)13.0 (4--64)11.0 (4--54)13.5 (4--34)27.5 (23--44)34, 6452M:F32:2023:86:61:52:00:10.129**0.014Clinical symptom** Cough30/52 (57.7)22/31 (71.0)4/12 (33.3)2/6 (33.3)2/2 (100)0/1 (0)**0.055**0.157 Dyspnea12/52 (23.1)11/31 (35.5)1/12 (8.3)0/6 (0)0/2 (0)0/1 (0)0.1610.151 Chest pain15/52 (28.8)9/31 (29.0)1/12 (8.3)4/6 (66.7)0/2 (0)1/1 (100)0.2990.157 Fever16/52 (30.8)10/31 (32.3)4/12 (33.3)0/6 (0)1/2 (50.0)1/1 (100)1.0000.162**Clinical stage** Stage I2/52 (3.8)0/31 (0)0/12 (0)2/6 (33.3)0/2 (0)0/1 (0)**0.023** Stage II13/52 (25.0)1/31 (3.2)7/12 (58.3)3/6 (50.0)1/2 (50.0)1/1 (100)**0.0010.010** Stage III13/52 (25.0)7/31 (22.6)5/12 (41.7)1/6 (16.7)0/2 (0)0/1 (0)0.2111.000 Stage IV24/52 (46.2)23/31 (74.2)0/12 (0)0/6 (0)1/2 (50.0)0/1 (0)**0.0000.001**Tumor size (cm)9.37 ± 3.2410.31 ± 2.747.82 ± 4.776.60 ± 1.42**0.2660.015**Ratio of TD to MTD0.47 ± 0.170.52 ± 0.150.45 ± 0.240.28 ± 0.07**0.5790.004Tumor compression or encasement** Blood vessels29/35 (82.9)23/23 (100)3/6 (50.0)2/4 (50.0)1/2 (50.0)**0.0050.017** Pericardium23/35 (65.7)18/23 (78.3)3/6 (50.0)1/4 (25.0)1/2 (50.0)0.3050.065 Trachea19/35 (54.3)14/23 (60.9)2/6 33.3)1/4 (25.0)2/2 (100)0.3640.294**Complication** Pleural effusion23/35 (65.7)21/23 (91.3)1/6 (16.7)0/4 (0)1/2 (50.0)**0.0010.001** Pericardial effusion14/35 (40.0)13/23 (56.5)1/6 (16.7)0/4 (0)0/2 (0)0.1690.098 Pneumonia17/35 (48.6)14/23 (60.9)1/6 (16.7)0/4 (0)2/2 (100)0.080**0.041**

### Histological subtypes and age groups {#Sec5}

The 52 patients, ranging from 4 to 64 years (median 13 years), were classified as 31 pediatric patients (from 4 to 18 years, median 8 years) and 21 adult patients (from 20 to 64 years, median 28 years). The pediatric patients presented with T-LBL/T-ALL and CHL in 24 and 7 cases, respectively. The adult patients presented with T-LBL/T-ALL, PMBL, CHL, DLBCL, and MALT lymphoma in 7, 6, 5, 2, and 1 cases, respectively. Pediatric patients had a significantly higher prevalence of T-LBL/T-ALL (24/31 and 77.4% vs. 7/21 and 33.3%; *P* = 0.001) and lower incidence of PMBL (0/31 and 0% vs. 6/21 and 28.6%; *P* = 0.003) than adult patients.

The ages of patients with T-LBL/T-ALL, CHL, and PMBL ranged from 4 to 54 years (median, 11 years), 4 to 34 years (median, 13.5 years), and 23 to 44 years (median, 27.5 years), respectively. The two DLBCL patients were 34 and 64 years old, and the MALT patient was 52 years old. T-LBL/T-ALL and CHL occurred in both pediatric and young adult patients, whereas PMBL exclusively occurred in young adults.

### Gender tendencies and age groups {#Sec6}

Pediatric patients were more likely to be male predilection with a M:F ratio of 22:9, as compared with adults of 10:11 (*P* = 0.089). Adult patients with T-LBL/T-ALL showed a male predominance with a M:F ratio of 6:1, compared to pediatric patients of 17:7. The tendency of male predominance in T-LBL/T-ALL patients seemed to be increased with age. Patients with PMBL and CHL presented with female predominance with the M:F ratios of 1:5 and 6:6 respectively. Patients with T-LBL/T-ALL showed a higher male predominance than patients with PMBL (*P* = 0.014).

### Initial presentations and age groups {#Sec7}

Five patients had been identified during physical examination without symptoms. Forty-seven patients exhibited various symptoms, including cough (30/52, 57.7%), chest pain (15/52, 28.8%), fever (16/52, 30.8%), dyspnea (12/52, 23.1%), and neck enlargement (6/52, 11.5%). Cough was the most common symptom in T-LBL/T-ALL patients (22/31, 71.0%) and chest pain was often presented in PMBL patients (4/6, 66.7%). Pediatric patients showed higher frequency of dyspnea than adults (12/31 and 38.7% vs. 0/21 and 0%; *P* = 0.001).

### Clinical stages and age groups {#Sec8}

Stages I, II, III, and IV were present in 0 (0%), 4 (12.9%), 8 (25.8%), and 19 (61.3%) pediatric patients, respectively, as well as in 2 (9.5%), 9 (42.9%), 5 (23.8%), and 5 (23.8%) adult patients, respectively. Compared to adults, pediatric patients more frequently presented stage IV disease (19/31 and 61.3% vs. 5/21 and 23.8%; *P* = 0.008) and less frequently presented II disease (4/31 and 12.9% vs. 9/21 and 42.9%; *P* = 0.034). T-LBL/T-ALL patients presented higher frequency with stage IV disease than CHL (*P* = 0.000) and PMBL (*P* = 0.001) patients, and less frequency with stage II presentation than CHL (*P* = 0.001) and PMBL (*P* = 0.010) patients.

### Clinical follow-up {#Sec9}

Six pediatric patients with T-LBL/T-ALL died due to progression of the disease during the process of therapy, 22 patients were still under treatment, and the other 24 patients were followed up from 10 to 35 months (mean, 23.5 months).

Radiological assessments {#Sec10}
------------------------

Radiological data of 50 cases were available, including computed tomography (CT), fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT), and magnetic resonance imaging (MRI) in 50, 21, and 1 cases, respectively. Radiological data of 35 cases were available at initial diagnosis, and the radiological features are summarized in Table [4](#Tab4){ref-type="table"}.Table 4Radiological characteristics of 52 cases with lymphomas involving the mediastinum.\*Case no.Histological subtypeLocationSize (cm)TD (cm)/MTD (cm) (ratio)Compression or encasementComplicationBlood vesselsPericardiaumTracheaPleural effusionPericardial effusionPneumonia**Pediatric patients**1T-LBL/T-ALLAnterior M11.311.3/17.2 (0.657)YYYYYN2T-LBL/T-ALLAnterior M8.88.8/17.9 (0.492)YYYYYY3T-LBL/T-ALLAnterior-superior M11.611.6/16.3 (0.712)YYYYYY4T-LBL/T-ALLAnterior and middle M14.114.1/16.5 (0.856)YYYYNY5T-LBL/T-ALLAnterior M13.513.5/18.5 (0.730)YYNYYY6T-LBL/T-ALLAnterior M8.68.6/17.7 (0.486)YYYYYN7T-LBL/T-ALLAnterior-superior M8.08.0/16.9 (0.473)YNYYYN8T-LBL/T-ALLNANANANANANANANANA9T-LBL/T-ALLNANANANANANANANANA10T-LBL/T-ALLNANANANANANANANANA11T-LBL/T-ALLAnterior M6.0NAYNNNNN12T-LBL/T-ALLNANANANANANANANANA13T-LBL/T-ALLAnterior-superior M6.06.0/18.9 (0.317)YYYYNY14T-LBL/T-ALLAnterior and middle M12.012.0/19.4 (0.619)YYYYYY15T-LBL/T-ALLAnterior-superior M8.98.9/23.4 (0.380)YYNYNY16T-LBL/T-ALLAnterior M9.89.8/21.8 (0.450)YYNYYN17T-LBL/T-ALLAnterior M13.513.5/20.8 (0.649)YYYYNN18T-LBL/T-ALLAnterior-superior M5.75.7/15.1 (0.377)YNNYNY19T-LBL/T-ALLAnterior M9.39.3/23.6 (0.394)YYNYYY20T-LBL/T-ALLAnterior-superior M6.16.1/23.8 (0.256)YNYNNN21T-LBL/T-ALLSuperior M10.710.7/22.2 (0.482)YNNYNN22T-LBL/T-ALLAnterior and middle M12.712.7/21.1 (0.602)YYYYYY23T-LBL/T-ALLNANANANANANANANANA24T-LBL/T-ALLAnterior M12.012.0/24.6 (0.488)YYNYNN25CHLNANANANANANANANANA26CHLAnterior M4.04.0/16.7 (0.239)NNNNNN27CHLAnterior-superior M10.010.0/14.6 (0.685)YYYNNN28CHLNANANANANANANANANA29CHLNANANANANANANANANA30CHLAnterior-superior M13.413.4/20.1 (0.658)YYYYYY31CHLAnterior-superior M3.0NANNNNNN**Adult patients**32T-LBL/T-ALLAnterior M12.012.0/24.9 (0.482)YYYYYY33T-LBL/T-ALLNANANANANANANANANA34T-LBL/T-ALLAnterior M11.911.9/23.4 (0.508)YYNYNY35T-LBL/T-ALLAnterior-superior M9.89.8/22.9 (0.428)YYYYYY36T-LBL/T-ALLAnterior M14.814.8/24.2 (0.612)YYYYYY37T-LBL/T-ALLNANANANANANANANANA38T-LBL/T-ALLNANANANANANANANANA39CHLAnterior-superior M3.83.8/24.3 (0.165)NNNNNN40CHLNANANANANANANANANA41CHLAnterior M12.712.7/24.3 (0.523)YYNNNN42CHLNANANANANANANANANA43CHLNANANANANANANANANA44PMBLAnterior M4.54.5/24.2 (0.186)NNNNNN45PMBLNANANANANANANANANA46PMBLNANANANANANANANANA47PMBLAnterior M7.47.4/22.1 (0.335)YYNNNN48PMBLAnterior-superior M7.07.0/26.9 (0.260)NNNNNN49PMBLAnterior M7.57.5/21.8 (0.344)YNYNNN50MALTNANANANANANANANANA51DLBCLAnterior M10.610.6/25.2 (0.421)YYYNNY52DLBCLMiddle M6.86.8/25.6 (0.266)NNYYNYAbbreviations: M, mediastinum; NA, not available; N, no; Y, yes.^\*^Case numbers are identical with the patient number used in Table [1](#Tab1){ref-type="table"}.

The anterior or both the anterior and the superior mediastinum was the most common location of mediastinal lymphomas (31/35, 88.6%), followed by both the anterior and middle mediastinum (3/35, 8.6%), and the middle mediastinum (1/35, 2.8%).

The tumor diameters (TD) were variable, ranging from 3 to 14.8 cm (mean, 9.4 cm), with pediatric patient tumor masses ranging from 3 to 14.1 cm (mean, 9.5 cm) and adult patient tumor masses ranging from 3.8 to 14.8 cm (mean, 9.1 cm). Bulky masses were more frequently revealed in T-LBL/T-ALL (mean, 10.3 cm) than in CHL (mean, 7.8 cm) and PMBL (mean, 6.6 cm) cases. The ratios of TD to maximum transthoracic diameter (MTD) in patients with T-LBL/T-ALL were higher than those of PMBL patients (0.52 ± 0.15 vs. 0.28 ± 0.07; *P* = 0.004). The ratios of TD to MTD in pediatric patients were significantly higher than those of adult patients (0.52 ± 0.17 vs. 0.38 ± 0.14; *P* = 0.015).

As shown in Fig. [1](#Fig1){ref-type="fig"} and Table [4](#Tab4){ref-type="table"}, tumor masses variably compressed or encased the blood vessels, pericardium, and trachea in 29 (29/35, 82.9%), 23 (23/35, 65.7%), and 19 (19/35, 54.3%) cases, respectively. T-LBL/T-ALL patients images exhibited greater tendency for compression of the blood vessels than CHL (*P* = 0.005) and PMBL (*P* = 0.017) patient.Figure 1Radiological characteristics of T-LBL/T-ALL involving the mediastinum, case 1. (**a**) Chest X-ray image shows a large mass in the mediastinum. (**b**) PET-CT image shows increased FDG activity in the mediastinum. (**c**) Axial contrast-enhanced CT scan shows the compression of pericardiaum. (**d**) Three-dimensional volume rendered image of contrast-enhanced CT exhibits the compression of pericardiaum. (**e**) Axial contrast-enhanced CT scan shows vascular compression and tracheal encasement of the mass. (**f**) Maximal intensity projection of contrast-enhanced CT reveals the encasement of superior vena cava.

Complications of lymphomas involving the mediastinum commonly included pleural effusion (23/35, 65.7%), pericardium effusion (14/35, 40.0%), and pneumonia (17/35, 48.6%). T-LBL/T-ALL patients presented with a higher frequency of pleural effusions than CHL and PMBL patients, (*P* = 0.001) for both, and pneumonia than PMBL patients (*P* = 0.041). Pediatric patients were likely higher prevalence of pleural effusion than adult patients (18/23 and 78.3% vs. 5/12 and 41.7%; *P* = 0.059).

Discussion {#Sec11}
==========

Lymphomas involving the mediastinum occur in a wide age range and demonstrate various clinical symptoms and radiological findings. However, the clinicopathological and radiological differences between pediatric and adult patients have not been clearly defined in previous reports^[@CR1],\ [@CR10]^.

As reported previously, each histological subtype exhibited distinct clinicopathological features^[@CR3]--[@CR6],\ [@CR14]^. However, comprehensive clinicopathological comparison among these subtypes is lacking in previous studies. In this study, pediatric patients exclusively presented with T-LBL/T-ALL and CHL, in contrast to adult patients, who presented with complex subtypes of T-LBL/T-ALL, CHL, PMBL, DLBCL, and MALT lymphomas. We further investigated the comparisons among different histological subtypes.

T-LBL/T-ALL is a highly aggressive neoplasm of lymphoblasts of T-cell origin. Due to the rapid growth of tumor cells, it is common for T-LBL/T-ALL patients to present with an advanced stage and unfavorable outcome as reported previously^[@CR15],\ [@CR16]^. In our results, T-LBL/T-ALL patients showed more frequent stage IV presentation than CHL and PMBL patients. Imaging of T-LBL/T-ALL patients commonly showed bulky masses, blood vessels compression, and pleural effusion.

PMBL is a common histological subtype in adult patients. PMBL patients are reported to have favorable clinical outcomes compared to patients with systemic DLBCL involving the mediastinum^[@CR17],\ [@CR18]^. In our study, PMBL occurred in young adults, who presented with a higher frequency of localized clinical stage than patients with T-LBL/T-ALL.

CHL occurs in both pediatric and adult patients^[@CR4]^. As shown in our study, the most common histological subtype was NSCHL. Previous reports have shown that NSCHL generally presents with localized disease and a better prognosis than other subtypes of CHL^[@CR19]^. Some patients have morphological features overlapping between NSCHL and PMBL, such as mediastinal gray-zone lymphoma, which makes pathological diagnoses challenging^[@CR20]^. Our results showed that an immunohistochemical profile of positivity for CD15 and CD30 was helpful for the diagnosis of CHL. In addition, distinguishing PMBL from CHL could also be based on the value of CD23, which has been confirmed previously^[@CR21]^.

Thymic MALT lymphomas are quite rare and occur most frequently in Asian females from 40 to 60 years of age. They often show an indolent course and localized disease^[@CR22]^. Thymic MALT lymphomas are distinct from MALT lymphomas of other sites in several ways, including gene abnormalities and geographic distribution^[@CR23]^. In the current study, the MALT lymphoma patient was a 52-year-old female who presented with stage II. In our study, 2 cases of systemic DLBCL with secondary mediastinal involvement were identified. Despite the pathological similarities to PMBL, DLBCL exhibited more aggressive clinical features and a poor outcome.

Although the discrimination of histological subtypes of lymphomas may be the most important reason for the clinical and radiological features, age-related differences of tumor biology, host characteristics, or treatment protocols also contribute to different outcomes between pediatric and adult patients. For example, pediatric type follicular lymphoma is considered to be a separate entity which differs from usual adult follicular lymphoma in clinical and pathological features^[@CR24],\ [@CR25]^.

Age is an important factor for lymphoma. Non-Hodgkin lymphoma (NHL) in pediatric patients present biological and epidemiological peculiarities that if better understood could help optimize their outcome. In order to investigate the influence of age on biology of lymphomas, we have compared pediatric and adult lymphomas in the same anatomic sties. As we reported recently, B-cell lymphomas involving the Waldeyer's ring had distinctive clinicopathological characteristics in pediatric patients compared to adult counterparts. A subset of cases belonged to the new entity of IRF4/MUM1 positive lymphoma^[@CR26],\ [@CR27]^.

Of note, for appropriate management of pediatric and adult lymphomas, different staging systems have been used. The original Ann Arbor staging system^[@CR28]^ and the updated Lugano classification^[@CR29]^ were designed without input from the pediatric NHL disease entities. The Murphy Classification^[@CR30]^ and the revised Pediatric Non-Hodgkin Lymphoma Staging system (IPNHLSS)^[@CR31]^ facilitated more precise staging for children and adolescents with NHL. However, few studies compared pediatric and adult patients with mediastinal NHL by the different staging systems. We assessed the clinical stages of pediatric and adult T-LBL/T-ALL patients using the revised IPNHLSS and the Lugano classification, respectively.

Despite of a population over 1300 million in China, to date, English information on mediastinal lymphomas of Chinese populations is limited. We described 52 cases of lymphomas involving the mediastinum, which exhibited a wide age range, heterogeneous histological subtypes, various clinical presentations and complex radiological manifestation. Compared to adult lymphomas, pediatric lymphomas presented distinctive histological subtypes, clinical behaviors, and radiological features. The limitation of this study is the relatively small number of cases, and further studies are needed for more detailed understanding.

Accordingly, this is the first multidisciplinary English report comprehensively compared the differences between Chinese pediatric and adult patients with mediastinal lymphomas and may provide new insight into the understanding of mediastinal lymphoma using different staging systems.

Materials and Methods {#Sec12}
=====================

Case selection {#Sec13}
--------------

Cases were obtained from a single Chinese institution: Shanghai Xinhua Hospital. A total of 506 patients with the mediastinal mass were reviewed between November 2011 and December 2016. Among these cases, 52 cases of lymphomas involving the mediastinum were identified and included in this study. The pathological diagnoses were originally established according to the criteria of the 2008 World Health Organization classification. All experimental protocols were approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine and performed in accordance with the approved guidelines of the institution. The appropriate informed consent was obtained from all subjects under the institutional review board-approved protocol.

Age grouping, clinical information, and staging {#Sec14}
-----------------------------------------------

The patients were arbitrarily defined as 2 groups, including pediatric group under 19 years of age and adult group over 19 years of age. The clinical data, including the age, gender, date of initial diagnosis, symptoms, clinical stage, serum lactate dehydrogenase level, medical records, and surgical records, were reviewed. The disease stages of CHL and adult NHL patients were assessed according to the Lugano Classification^[@CR29]^ and pediatric NHL patients to the IPNHLSS^[@CR31]^.

Radiological modalities {#Sec15}
-----------------------

The patients were identified by imaging assessments including chest X-ray, CT, MRI, or PET-CT.

Histological and immunohistochemistry analyses {#Sec16}
----------------------------------------------

Formalin-fixed paraffin-embedded tissues were stained with hematoxylin and eosin at the initial diagnosis. Immunohistochemistry was performed using the following panel of monoclonal and polyclonal antibodies: CD20 (clone L26, DAKO, Glostrup, Denmark); CD79a (clone 1.10E + 04, Leica Biosystems, Wetzlar, Germany); PAX5 (clone R1, DAKO); CD10 (clone 56C6, Leica Biosystems); BCL6 (clone P1F6, DAKO); MUM1 (clone MUM1p, DAKO); Ki-67 (clone MIB-1, DAKO); Terminal deoxynucleotidyl transferase (TDT, clone SP150, DAKO); CD2 (clone AB75, DAKO); CD3 (clone LN10, Leica Biosystems); CD4 (clone SP35, DAKO); CD7 (DAKO); CD8 (clone SP16, DAKO); CD1a (clone SP157, DAKO); CD34 (clone QBEnd/10, DAKO); CD43 (clone DF-T1, DAKO); CD99 (clone HO36-1.1, DAKO); CD117 (clone C-KIT, DAKO); CD45 (clone PAN-LCAL, DAKO); CD33 (clone WM-54, DAKO); MPO (clone SP72, DAKO); CD15 (clone C3D-1, DAKO); CD30 (clone Ber-H2, DAKO); CD23 (clone SP23, DAKO); and Epithelial membrane antigen (EMA, clone GP1.4, Leica Biosystems).

Statistical analysis {#Sec17}
--------------------

Statistical analyses were performed with SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA). Chi-squared and Fisher's exact tests were used to determine correlation in the frequencies between groups. The TD to MTD were summarized using the mean and standard deviation. Two tailed independent samples t-test were used to assess statistical significance in comparisons between the pediatric and adult patients.
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